Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...
Pharmalittle: We’re reading about Lilly and Roche weight loss drugs, FDA and compounders, and more
Three U.S. senators are calling on Robert Kennedy Jr. to disclose what he and President Trump discussed with drugmakers ...
Zacks Investment Research on MSN13h
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
Novo Nordisk (NVO) stock in focus as company launches its direct-to-consumer platform NovoCare Pharmacy for Wegovy delivery.
It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. Let's figure out ...
Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...
Eli Lilly's performance in the biopharmaceutical sector reflects its strong market position, despite facing challenges. The ...
Eli Lilly and Company is unveiling its new 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, which will be available ...
Eli Lilly LLY-2.01%decrease; red down pointing triangle is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using their health plans ...
Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
Eli Lilly released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without insurance coverage for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback